Full Fed. Circ. Rejects Mylan Rehearing Bid In Patent Case

The full Federal Circuit on Tuesday shot down Mylan's request for the court to reconsider a March ruling that the company's planned generic version of schizophrenia drug Invega Trinza would cause...

Already a subscriber? Click here to view full article